Valuation: Grifols, S.A.

Market Cap 5.88B 6.81B 5.52B 5.03B 9.45B 651B 9.58B 64.76B 25.34B 326B 25.56B 25B 1,085B P/E 2026 *
12.5x
P/E 2027 * 9.56x
Enterprise Value 14.33B 16.59B 13.45B 12.25B 23.01B 1,586B 23.34B 158B 61.73B 794B 62.26B 60.9B 2,644B EV / Sales 2026 *
1.87x
EV / Sales 2027 * 1.72x
Free-Float
79.65%
Yield 2026 *
2.81%
Yield 2027 * 3.07%
1 day-2.96%
1 week-1.50%
Current month-5.76%
1 month+6.50%
3 months+0.77%
6 months-14.94%
Current year-13.82%
1 week 6.55
Extreme 6.55
6.75
1 month 6.15
Extreme 6.15
7.1
Current year 5.95
Extreme 5.95
8.35
1 year 5.95
Extreme 5.95
9.3
3 years 4.78
Extreme 4.78
10.6
5 years 4.78
Extreme 4.78
13.1
10 years 4.78
Extreme 4.78
23.4
Manager TitleAgeSince
Chief Executive Officer 58 01/04/2024
Director of Finance/CFO 49 16/09/2024
Compliance Officer 54 01/01/2014
Director TitleAgeSince
Chairman 76 25/01/2010
Director/Board Member 70 13/04/2000
Director/Board Member 62 24/05/2015
Change 5-day change 1-year change 3-year change Capi.($)
-2.96%-1.50% - - 6.86B
+0.30%+2.75%+38.86%+1.08% 80.23B
-1.02%-0.51%-2.54%+28.91% 50.64B
+1.46%-3.45%+11.90%+164.29% 46.87B
-1.39%+1.82%-50.22%-50.44% 46.34B
-0.32%+0.58%+50.90%-21.15% 31B
+1.80%+8.94%+130.05%-34.84% 25.28B
+2.78%+2.44%+42.08%+90.79% 24.36B
+1.65%+0.53%-2.21%+190.26% 20.81B
+3.95%+1.02%+67.20%+117.59% 16.08B
Average +0.30%+0.35%+31.78%+54.05% 37.96B
Weighted average by Cap. +0.22%+0.53%+23.84%+39.34%

Financials

2026 *2027 *
Net sales 7.66B 8.87B 7.19B 6.54B 12.3B 848B 12.47B 84.31B 32.99B 424B 33.27B 32.55B 1,413B 8.13B 9.42B 7.64B 6.95B 13.07B 901B 13.25B 89.59B 35.05B 451B 35.35B 34.58B 1,501B
Net income 536M 620M 503M 458M 860M 59.3B 873M 5.9B 2.31B 29.7B 2.33B 2.28B 98.85B 699M 810M 657M 598M 1.12B 77.42B 1.14B 7.7B 3.01B 38.78B 3.04B 2.97B 129B
Net Debt 8.45B 9.78B 7.93B 7.22B 13.57B 935B 13.76B 93.01B 36.39B 468B 36.7B 35.9B 1,559B 8.1B 9.38B 7.61B 6.93B 13.02B 897B 13.2B 89.25B 34.92B 449B 35.22B 34.45B 1,496B
Logo Grifols, S.A.
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (86.2%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (8.5%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.1%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.2%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.6%), European Union (15.9%), the United States and Canada (56.5%) and other (22%).
Employees
25,258
Date Price Change
17/08/26 €6.550 -2.96%
14/08/26 €6.750 0.00%
13/08/26 €6.750 0.00%
12/08/26 €6.750 0.00%
11/08/26 €6.750 +0.75%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
9.814EUR
Average target price
14.53EUR
Spread / Average Target
+48.09%

Quarterly revenue - Rate of surprise